Does a higher omega-6 to omega-3 ratio promote pro-inflammatory eicosanoid signaling?

The balance of dietary and cellular fatty acids plays a critical role in regulating systemic inflammation, particularly through the ratio of omega-6 arachidonic acid (AA) to omega-3 eicosapentaenoic acid (EPA).

Mechanistic substrate competition

• Enzymatic competition: Both AA and EPA utilize the same cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic pathways. Because these enzymes do not strongly discriminate between the two substrates, they catalyze metabolism based primarily on substrate availability.
• Pro-inflammatory shift: An elevated omega-6 to omega-3 (or AA to EPA) ratio allows AA to outcompete EPA for enzyme active sites. This competitive substrate occupancy accelerates the synthesis of highly active, AA-derived pro-inflammatory lipid mediators.
• Key mediators: This enzymatic preference shifts lipid mediator production toward series-2 prostaglandins, particularly prostaglandin E2 (PGE2), and series-4 leukotrienes, such as leukotriene B4 (LTB4), while suppressing the conversion of omega-3 fatty acids.

Physiological and inflammatory impacts

• Inflammatory signaling and pain: PGE2 is a potent mediator that drives inflammatory signaling, increases vascular permeability, and heightens nociceptor sensitivity, contributing directly to inflammatory pain.
• Leukocyte recruitment: LTB4 acts as a highly powerful chemoattractant, driving neutrophil chemotaxis and leukocyte recruitment to tissues, which sustains chronic inflammatory tone.
• Resolution pathways: Conversely, lowering the AA to EPA ratio shifts enzymatic output toward series-3 prostaglandins (PGE3) and series-5 leukotrienes (LTB5)—which possess significantly lower inflammatory potency—and increases the generation of specialized pro-resolving mediators (such as resolvins) that actively limit tissue damage.

Bottom line

• An elevated omega-6 to omega-3 (or AA to EPA) ratio directly drives pro-inflammatory signaling by allowing arachidonic acid to outcompete EPA for shared COX and LOX enzymes, yielding highly potent inflammatory mediators like PGE2 and LTB4 instead of weaker or pro-resolving alternatives.